This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Diagnosed with heterozygous familial hypercholesterolemia
Adult between 18 and 50 years old
LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion
Renal insufficiency, defined as eGFR < 30 ml/min
History of atherosclerotic cardiovascular events
Atrial fibrillation
Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
Adult (newly diagnosed) heterozygous FH patients between 18 and 50 years with non-calcificated plaque on coronary CT angiography and who are not optimally treated yet.
Cohort
Prospective
Not listed
CAD Progression
Difference in total plaque volume between the initial and follow-up CCTA scan
Non-calcified plaque progression
Difference in non-calcified plaque volume between the baseline and follow-up CCTA scan
Calcified plaque progression
Difference in calcified plaque volume between the baseline and follow-up CCTA scan
Number of high-risk plaques
Difference in number of high-risk plaques between the baseline and follow-up CCTA scan
Difference in Pericoronary Adipose Tissue Attenuation
Difference in Pericoronary Adipose Tissue Attenuation between the baseline and follow-up CCTA scan
Click on the lead sponsor to view all of their trials.
